Hydrocodone controlled-release - Pernix Therapeutics

Drug Profile

Hydrocodone controlled-release - Pernix Therapeutics

Alternative Names: AFI-001; Hydrocodone bitartrate; Hydrocodone ER; Hydrocodone extended release; Zohydro ER; ZX 007; ZX-002

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Daravita
  • Developer Altus Formulation Inc; Pernix Therapeutics Holdings; Zogenix
  • Class Antitussives; Morphinans; Opioid analgesics; Opioid peptides; Small molecules
  • Mechanism of Action Opioid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Pain

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Pain(In volunteers) in USA (PO, Controlled release)
  • 23 Feb 2017 United States District Court for the District of Delaware accepts Patent infringement filed against Actavis by Pernix for infringement of patents U.S. Patent Nos. 9 132 096 and 6 902 742 by Actavis for the proposed generic versions of hydrocodone controlled release in USA
  • 14 Sep 2016 Pernix Therapeutics has patent protection for controlled-release hydrocodone in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top